Croma-Pharma Advances Global Reach with Novaestiq's Integration into Waldencast.

Croma-Pharma GmbH, an industry leader in minimally invasive aesthetic solutions based in Austria, celebrates a strategic milestone as Novaestiq Corp., a joint venture between Croma-Pharma and Gore Range Capital, is acquired by Waldencast plc. This acquisition marks a pivotal moment in Croma-Pharma's international expansion strategy, reinforcing its commitment to delivering high-quality and scientifically validated aesthetic products. The acquisition also heralds the launch of Saypha®ChIQ™ and Saypha®MagIQ™ injectables in the U.S. under the Obagi Medical brand, following FDA approval. Saypha®, renowned for its safety and efficacy, has become a top choice globally in over 80 markets. The collaboration promises significant innovation and inclusivity, aiming to deliver aesthetic care across diverse demographics. Croma-Pharma's deep experience in hyaluronic acid products, with 110 million syringes produced, enhances its strategic position as it partners with Waldencast to reach a wider audience.